Company’s 36-month beta value is -1.02.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TVGN is 21.96M, and currently, short sellers hold a 14.53% ratio of that floaft. The average trading volume of TVGN on November 04, 2024 was 14.74M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TVGN) stock’s latest price update
Tevogen Bio Holdings Inc (NASDAQ: TVGN)’s stock price has gone decline by -12.24 in comparison to its previous close of 2.37, however, the company has experienced a -24.09% decrease in its stock price over the last five trading days. globenewswire.com reported 2024-10-31 that WARREN, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) — Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, shares details of its partnership with Microsoft (Nasdaq: MSFT) for Startups.
TVGN’s Market Performance
TVGN’s stock has fallen by -24.09% in the past week, with a monthly rise of 645.52% and a quarterly rise of 353.36%. The volatility ratio for the week is 16.60% while the volatility levels for the last 30 days are 33.47% for Tevogen Bio Holdings Inc The simple moving average for the past 20 days is 21.98% for TVGN’s stock, with a -11.05% simple moving average for the past 200 days.
TVGN Trading at 121.43% from the 50-Day Moving Average
After a stumble in the market that brought TVGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.14% of loss for the given period.
Volatility was left at 33.47%, however, over the last 30 days, the volatility rate increased by 16.60%, as shares surge +560.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +263.79% upper at present.
During the last 5 trading sessions, TVGN fell by -22.99%, which changed the moving average for the period of 200-days by -81.23% in comparison to the 20-day moving average, which settled at $1.71. In addition, Tevogen Bio Holdings Inc saw -81.31% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TVGN starting from Flomenberg Neal, who sale 1,078,600 shares at the price of $1.62 back on Oct 17 ’24. After this action, Flomenberg Neal now owns 4,254,302 shares of Tevogen Bio Holdings Inc, valued at $1,747,332 using the latest closing price.
Desai Kirti, the Chief Financial Officer of Tevogen Bio Holdings Inc, purchase 3,000 shares at $0.82 during a trade that took place back on Jun 12 ’24, which means that Desai Kirti is holding 9,699,186 shares at $2,460 based on the most recent closing price.
Stock Fundamentals for TVGN
The total capital return value is set at 5.39. Equity return is now at value 268.90, with 22.57 for asset returns.
Based on Tevogen Bio Holdings Inc (TVGN), the company’s capital structure generated -0.36 points at debt to capital in total, while cash flow to debt ratio is standing at -3.0. The debt to equity ratio resting at -0.26. The interest coverage ratio of the stock is -95.6.
Currently, EBITDA for the company is -2.27 million with net debt to EBITDA at 0.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.23.
Conclusion
In a nutshell, Tevogen Bio Holdings Inc (TVGN) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
